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Macrophages and dendritic cells: 
what is the difference?
D Ferenbach1 and J Hughes1
Segerer et al. report the expression and localization of macrophage 
and dendritic-cell markers in human renal biopsies and indicate 
that both cell types express CD68, findings that resonate with 
murine studies. The functional and phenotypic distinction between 
macrophages and dendritic cells is discussed.
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Introduction
Macrophages and dendritic cells are key 
players in many renal diseases, such that 
modulation of their function holds thera-
peutic promise. Until recently they have 
been regarded as relatively discrete cell 
types, with macrophages being a key com-
ponent of the innate immune system while 
dendritic cells interface with the adaptive 
immune system and modulate immune 
responses. During disease, dendritic cells 
may initiate autoimmune responses and 
stimulate T cells with resultant macro-
phage activation inducing signiﬁcant tissue 
damage. There are, however, additional 
complexities, including the involvement 
of macrophages in tissue homeostasis and 
repair and the tolerogenic actions of den-
dritic cells under normal circumstances 
and during disease states; these functions 
may act to prevent or limit tissue injury 
as well as promote the resolution process. 
Such a model regards macrophages and 
dendritic cells as clearly separated in terms 
of cellular function while occupying over-
lapping anatomical sites in peripheral 
tissues and the reticuloendothelial sys-
tem. In practice, distinguishing between 
macrophages and dendritic cells has relied 
on the use of cell-surface markers thought 
to be speciﬁc to either cell. The progres-
sive reﬁnement and increasing number of 
available markers have served to compli-
cate rather than simplify our understand-
ing of the renal mononuclear phagocyte 
system, and this is highlighted in the study 
by Segerer et al.1 (this issue).
Dendritic-cell markers in human disease
Segerer et al.1 examined a variety of 
contemporary cell markers in 55 human 
renal biopsies, including normal tissue, 
non-proliferative glomerulonephritis 
(focal segmental glomerulosclerosis, 
membranous nephropathy, and minimal-
change disease), and proliferative 
glomerulonephritis (necrotizing and 
lupus glomerulonephritis). The cell 
markers used were CD68 (macrosialin; 
conventionally regarded as a macro-
phage marker), dendritic cell-speciﬁc 
ICAM-3-grabbing nonintegrin (DC-
SIGN; a marker of myeloid dendritic 
cells), blood dendritic-cell antigen-2 
(BDCA-2; a marker of plasmacytoid 
dendritic cells), S-100 (expressed by 
Langerhans cells and dendritic cells), and 
langerin (expressed by Langerhans cells). 
DC-SIGN+ cells (myeloid dendritic cells) 
coexpressed CD68 and were found in 
abundance in the tubulointerstitium 
but were intriguingly absent in glomer-
uli. Woltman et al.2 also noted limited 
glomerular numbers of DC-SIGN+ cells 
in IgA nephropathy. CD68+/DC-SIGN– 
cells (macrophages) were found in sig-
nificant numbers in the glomeruli of 
patients with proliferative nephritis but 
also inﬁltrated the tubulointerstitium. 
BDCA-2+ plasmacytoid dendritic cells 
were present in the tubulointerstitium 
and tended to form follicular aggregates, 
whereas S-100+ or langerin+ dendritic 
cells were rare. Langerin+ dendritic cells 
were, however, intimately associated with 
the collecting ducts, with this localization 
implying a potential sentinel function for 
ascending infections.
The specificity of cell markers
This study raises a number of important 
issues that will need to be taken into 
account by investigators in the future. For 
example, the cell-surface marker CD68 
does not distinguish between macro-
phages and dendritic cells (Figure 1). This 
resonates with recent murine studies indi-
cating that the F4/80 marker detects both 
macrophages and dendritic cells that are 
resident within or inﬁltrating the kidney.3 
Indeed, the F4/80 knockout mouse exhib-
its defective generation of antigen-speciﬁc 
regulatory T cells in an ocular model of 
inflammation, indicating that F4/80+ 
cells exert important immunoregulatory 
actions.4 Although dendritic-cell markers 
exist, it is also noteworthy that both mac-
rophages and dendritic cells can express 
major histocompatibility complex class II. 
We may need to reassess our usage of 
names given to cells such as macrophages 
or dendritic cells despite the fact that they 
have a long history. For example, the resi-
dent sentinel cell of the lung is CD11c+ 
but is generally referred to as an alveolar 
macrophage! Although such ‘names’ are 
useful, it may be best to simply addition-
ally describe cells by the particular set of 
markers expressed together with their 
purported function. Also, the ﬁndings of 
previously published studies may need to 
be reappraised in the light of the nonspe-
ciﬁcity of some cell-surface markers, such 
as CD68 and F4/80.
A requirement for readouts of  
cell function
Although descriptive studies are often 
informative, it can be diﬃcult to deter-
mine whether the cells within the tis-
sue are directly involved in mediating 
the disease process or simply reflect 
a response to the tissue injury. This 
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is a key area, as the leukocyte popula-
tion within the diseased kidney will be 
heterogeneous and contain both pro-
inﬂammatory and reparative cells. Thus, 
additional interrogation will be required 
to determine the functional phenotype 
of inﬁltrating or resident cells. Various 
markers that reﬂect the state of macro-
phage activation, such as expression of 
inducible nitric oxide synthase, man-
nose receptor, arginase, FIZZ1 (found 
in inflammatory zone 1), and so on, 
have been described, and these may be 
informative (reviewed by Gordon5). In 
experimental studies the infiltrating 
leukocyte population may be negatively 
or positively immunopuriﬁed following 
enzymatic dissociation of inﬂamed kid-
neys. The nature of these isolated cells 
can then be examined by approaches 
such as ﬂow cytometry, quantitative real-
time PCR, microarray, and proteomics. 
Such an approach is not so readily fea-
sible for human tissue, but laser capture 
microscopy and subsequent analysis of 
gene expression signatures may provide 
insights into the phenotype of leukocytes 
present within diseased kidneys.
Experimental models of cell ablation
How can we explore the role of macro-
phages and dendritic cells in experimen-
tal models of renal inﬂammation? The 
administration of liposomal clodronate 
has long been used as a means to deplete 
‘macrophages,’ but we have found that 
renal resident F4/80+/CD11c+ dendritic 
cells are also reduced by this treatment. 
Indeed, any experimental manipulation 
that reduces circulating monocyte num-
bers will have an eﬀect on the develop-
ment of inﬂammatory myeloid dendritic 
cells, as these cells are derived from 
recruited monocytes.6 Transgenic con-
ditional cell-ablation models using the 
restricted expression of the human diph-
theria toxin receptor (DTR) have been 
developed and have proved useful. Vari-
ous mice have already been generated, 
including the CD11b-DTR mouse,7 the 
CD11c-DTR mouse, and a langerin-DTR 
mouse.8 Further conditional depletion 
systems may become feasible as murine 
homologues of markers such as DC-SIGN 
and so on are found. Although such stud-
ies undoubtedly generate useful informa-
tion, there are caveats to the interpretation 
of such models. For example, the induc-
tion of widespread apoptosis is not a 
‘neutral’ event from the immunological 
and inﬂammatory perspective, as apop-
totic cells may exert anti-inﬂammatory 
eﬀects on both macrophages and den-
dritic cells.
Tubulointerstitial versus glomerular 
localization
The study by Segerer et al.1 highlights the 
diﬀerential localization of macrophages 
and dendritic cells, with dendritic cells 
appearing to be restricted to the tubu-
lointerstitium. The authors speculate that 
this may prevent the generation of an 
immune response to antigens within the 
glomerulus or might reﬂect an absence 
of glomerular lymphatic vessels to allow 
the egress of dendritic cells to draining 
lymph nodes. It may, however, be the 
case that the postglomerular sampling of 
ﬁltered antigen is more important, and 
recent work indicates a role for ﬁltered 
renal antigen in maintaining peripheral 
tolerance,9 though the concentrated 
antigen gains access to draining lymph 
nodes by dendritic cell-dependent and 
independent mechanisms. The location 
of dendritic cells within the tubulointer-
stitium may represent the optimal loca-
tion, as they can access ﬁltered antigen, 
intravascular antigen, and any ascending 
pathogens with comparative ease.
The mononuclear phagocyte system: 
‘cellular spectrum’
The work of Segerer et al.1 should be 
set in the context of the growing body 
of evidence that demonstrates the plasti-
city of both functions and surface mark-
ers between cells of the mononuclear 
phagocyte system.10 Accordingly, it 
may be more sensible to regard macro-
phages and dendritic cells as cells that 
exist on a spectrum (Figure 1) where 
cells may express variable sets of cell-
surface markers and functions. For 
example, dendritic cells are believed to 
be important for detecting and reacting 
to tissue injury or infection as well as 
regulating immune responses through 
antigen presentation, T-cell stimulation, 
or the generation of regulatory T cells. 
However, CD11c– macrophages can 
eﬀectively present antigen and stimulate 
Figure 1 | Recent advances in the study of both functional characteristics and surface 
markers of the cells of the mononuclear phagocyte system have led to increasing overlap 
between what is considered a ‘macrophage’ and a ‘dendritic cell’. Abbreviations: CSF1-R, 
colony-stimulating factor 1 receptor; BDCA-1, blood dendritic-cell antigen-1; DC-SIGN, dendritic 
cell-specific ICAM-3-grabbing nonintegrin; MHC II, major histocompatibility complex class II.
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T cells11 and undoubtedly play a role as 
sentinel cells in various tissues. Also, 
several investigators have demonstrated 
that subcapsular splenic macrophages 
can eﬀectively present antigen to B cells 
(reviewed by Martinez-Pomares and 
Gordon12). Activated macrophages have 
been regarded as important mediators of 
host tissue damage, as they can induce 
apoptosis through a variety of mecha-
nisms, but recent work has also demon-
strated that dendritic cells may express 
high levels of inducible nitric oxide syn-
thase13 and induce cell death.14
Conclusion
The work by Segerer et al.1 has carefully 
utilized various cell markers to identify 
macrophages and dendritic cells within 
normal and diseased human renal tissue 
and has demonstrated diﬀerential and 
distinctive spatial localization. The chal-
lenge for the future is to understand the 
nature and function of these various cell 
types together with the factors that lead 
to their particular localization within the 
kidney. This may generate insights into 
which cells represent the best target for 
modulating the inﬂammatory process and 
augmenting subsequent tissue repair.
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Setting the stage for acute-on-
chronic kidney injury
JW Dear1 and PST Yuen2
Acute-on-chronic kidney disease will be familiar to many 
nephrologists. Hsu et al. quantify the risk of acute-on-chronic disease 
across the stages of preexisting chronic kidney disease. Their study 
demonstrates the valuable insights that large epidemiological 
studies can bring to the field of acute kidney injury.
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Several studies have shown that the prev-
alence of chronic kidney disease (CKD) 
is increasing,1 by consensus deﬁnitions 
developed by the Kidney Disease Out-
comes Quality Initiative (K/DOQI). 
These deﬁnitions and staging of CKD 
allow researchers to compare disease 
prevalence across time and across pop-
ulations and establish links between 
CKD and other diseases.2 For example, 
it is well established that CKD is a risk 
factor for cardiovascular disease, and 
this risk is significant even with mild 
impairment of kidney function.3 Hsu 
and colleagues4 (this issue) explore the 
relationship between CKD stage and the 
risk of developing acute kidney injury 
(AKI). They demonstrate that even mild 
chronic impairment of kidney function 
signiﬁcantly increases the risk of AKI.
Patients with ‘acute-on-chronic’ kidney 
disease should be familiar to most neph-
rologists. In terms of clinical practice, 
one of the strengths of the study by Hsu 
et al.4 is the quantiﬁcation of the rela-
tionship between CKD stage and risk of 
in-hospital, dialysis-requiring, AKI. The 
authors studied a large patient group, 
adults from a Kaiser Permanente cohort 
in northern California. By deﬁnition, this 
population has health insurance, and we 
hope future studies include patients with-
out insurance. The staging of ‘baseline’ 
CKD was based on outpatient measure-
ments of serum creatinine that predated 
the index episode of AKI, a signiﬁcant 
advantage over inferring baseline cre-
atinine from in-hospital measurements. 
This strategy allows for a more inclusive 
and perhaps more accurate view of the 
acute-on-chronic population. When 
the incidence of dialysis-requiring AKI 
was compared across the CKD stages, 
the authors found that “the propensity 
to develop in-hospital acute kidney fail-
ure is another complication of chronic 
